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Abstract/Summary  
 
Gut microbes are capable of producing most neurotransmitters found in the human brain.  
While these neurotransmitters primarily act locally in the gut, modulating the enteric 
nervous system, evidence is now accumulating to support the view that gut microbes 
through multiple mechanisms can influence central neurochemistry and behavior.  This 
has been described as a fundamental paradigm shift in neuroscience.  Bifidobacteria for 
example can produce and increase plasma levels of the serotonin precursor tryptophan, 
which is fundamental in regulating mood, appetite and gastrointestinal function.  Certain 
Lactobacilli have been shown to produce gamma-aminobutyric acid (GABA) and to alter 
brain GABA receptor expression and behavior.  IBS is regarded as the prototypic 
disorder of the brain-gut-microbiota axis which can be responsive to probiotic therapy.  
Recently, the concept of a psychobiotic has been introduced in the literature. A 
psychobiotic is a bacteria which when ingested in adequate amounts can have a positive 
mental health benefit.  Translational studies indicate that certain bacteria may impact 
upon stress responses and cognitive functioning.  Manipulating the gut microbiota with 
psychobiotics, prebiotics or even antibiotics offers a novel approach to altering brain 
function and treating gut-brain axis disorders such as depression and autism. 
 
Key Points  
 
• Gut microbes can communicate with the brain through a variety of routes 
including the vagus nerve, short chain fatty acids, cytokines and tryptophan 
• Psychobiotics are bacteria which when ingested in adequate amounts produce a 
positive mental health benefit. 
• The brain-gut-microbiota axis represents a paradigm shift in neuroscience and 
provides a novel target for treating not just IBS but conditions such as depression, 
autism and Parkinson’s disease. 
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Introduction 
 
The human adult gut contains over 1kg of bacteria, essentially the same weight as the 
human brain1.  It is generally estimated that the gut is inhabited by 1013-1014 micro-
organisms, which is more than ten times the number of human cells in our bodies and 
contains over 100 times as many genes as in our genome2. Amazingly, the genomic and 
biochemical complexity of the microbiota exceeds that of the brain. Studies of the brain-
gut-microbiota axis have been described as a paradigm shift in neuroscience 3. Increasing 
evidence points to the fact that appropriate diversity in the gut microbiota is not only 
essential for gut health but also for normal physiological functioning in other organs and 
especially the brain. An altered gut microbiota in the form of dysbiosis at the extremes of 
life, both in the neonate and in the elderly, can have a profound impact on brain function. 
Such a dysbiosis might emerge for a variety of reasons including the mode of birth 
delivery, diet, antibiotic and other drug exposure.  Given the fact that the brain is 
dependent on gut microbes for essential metabolic products it is not surprising that a 
dysbiosis can have serious negative consequences for brain function both from a 
neurological and mental health perspective.  While much of the early data emerged from 
animal studies, mainly rodent based, there are now an increasing number of human 
studies translating the animal findings.  
In this review we will focus upon the routes of communication between the gut and brain, 
examine a prototypic disorder of the brain gut axis, explore the ways in which gut 
dysbiosis may evolve and provide an up-to-date account of behavioral and neurological 
pathologies associated with dysbiosis. 
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Brain-gut-microbiota communication  
The brain-gut-microbiota axis is a bidirectional communication system enabling gut 
microbes to communicate with the brain, and the brain with the gut 4. While brain-gut 
communication has been a subject of investigation for decades an exploration of gut 
microbes within this context has only featured in recent years. The mechanisms of signal 
transmission are complex and not fully elucidated, but include neural, endocrine, 
immune, and metabolic pathways 5,6.  Preclinical studies have implicated the vagus nerve 
as a key route of neural communication between microbes of the gut and centrally-
mediated behavioural effects, as demonstrated by the elimination of central Lactobacillus 
rhamnosus effects following vagotomy7 and the fact that humans who have underwent 
vagotomy at an early age have a decreased risk of certain neurological disorders8. The gut 
microbiota also regulates key central neurotransmitters such as serotonin by altering 
levels of precursors; for example Bifidobacterium infantis has been shown to elevate 
plasma tryptophan levels and thus influence central 5-HT transmission9.  Intriguingly, 
synthesis and release of neurotransmitters from bacteria has been reported; Lactobacillus 
and Bifidobacterium species can produce gamma-aminobutyric acid (GABA): 
Escheridia, Bacillus and Saccharomyces spp. can produce noradrenaline: Candida, 
Streptococcus, Escheridia and Enterococcus spp. can produce serotonin: Bacillus can 
produce dopamine: and Lactobacillus can produce acetylcholine 10,11. These microbially 
synthesised neurotransmitters can cross the mucosal layer of the intestines, though it is 
highly unlikely that they directly influence brain function.  Even if they enter the blood 
stream, which is by no means certain, they are incapable of crossing the blood brain 
barrier (BBB).  Their impact on brain function is likely to be indirect acting on the enteric 
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nervous system.  Short chain fatty acids (SCFAs) which include butyrate, propionate and 
acetate are  essential metabolic products of gut microbial activity and may exert central 
effects either through G-protein coupled receptors, though such receptors are sparsely 
concentrated in the brain.  It is more likely that they act as epigenetic modulators through 
histone deacetylases (HDACs)2. SCFAs are also involved in energy balance and 
metabolism, and can modulate adipose tissue, liver tissue and skeletal muscle and 
function 12. Immune signalling from gut to brain mediated by cytokine molecules is 
another documented route of communication 13. Cytokines produced at the level of the 
gut can travel via the bloodstream to the brain.  Under normal physiological 
circumstances it is unlikely that they cross the BBB, but increasing evidence indicates a 
capacity to signal across the BBB and to influence brain areas such as the hypothalamus 
where the BBB is deficient. It is through the latter mechanism the cytokines interleukin 
(IL)-1 and IL-6 activate the hypothalamic-pituitary-adrenal axis (HPA), bringing about 
the release of cortisol.  This is the most potent activator of the stress system. 
The HPA which provides the core regulation of the stress response can  significantly 
impact the brain-gut-microbiota axis 14-20.  It is increasingly clear and probably of 
relevance in a number of pathological conditions that psychological or physical stress can 
significantly dysregulate the HPA and subsequently the brain-gut-microbiota axis, for 
example in IBS21.  
---Insert Fig. 1 here--- 
Multiple lines of approach have been used to interrogate the brain-gut-microbiota axis 
especially in animal model systems; these include the use of germ-free animals, potential 
probiotic agents, antibiotics, animals exposed to pathogens and the use of stress to 
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determine the effects of dysregulating the axis. The largest naturalistic study of a gut 
pathogen and the impact on the brain-gut axis was as a result of the Walkerton 
catastrophe. The contamination of the Walkerton water supply occurred  in 2000 claimed 
seven lives and  left over two thousand people ill. The E. coli outbreak was caused by 
farm runoff contaminating the town’s water supply.  Those infected had significant risk 
of developing post-infective-IBS and many had co-morbid depression/anxiety22. To a 
greater extent than any prior study this natural disaster provided clear cut support for the 
notion of post-infective IBS. 
Brain-gut-microbiota axis and extremes of life 
The intestinal microbiota of newborn infants is characterized by low diversity and a 
relative dominance of the phyla Proteobacteria and Actinobacteria in the early post-natal 
period, a time at which there is enormous brain development.  With the passage of time, 
the microbiota becomes more diverse with the emergence and dominance of Firmicutes 
and Bacteroidetes 23-25.  Full-term, vaginally delivered babies born to healthy mothers 
who are breast fed and non-antibiotic treated have an optimal  development of the 
neonatal microbiota 26.  The characteristic intestinal microbiota observed in healthy full-
term infants is disturbed in preterm infants 27, who are frequently delivered by caesarean 
section, receive antibiotics and may have problems feeding 28.  Furthermore, preterm 
infants possess a functionally immature gut with low levels of acidity in the stomach, due 
to insufficient gastric acid secretion and their requirement for more frequent feeding 28-30.  
These events lead to an increase in the prevalence of potentially pathogenic bacteria in 
the GI tract and less microbial diversity than full term infants 31-33.  The extent to which 
these features play a role in the development of cerebral palsy and subsequent autism are 
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the subject of research and ongoing debate 34.  What is clear is that complex brain 
maturation and the increasing sophistication of the gut microbiota are highly correlated. 
To date many of our assumptions are based on correlational data from which we cannot 
conclusively conclude a causative impact. 
When elderly people in nursing homes are compared with those in the community large 
scale differences are detected.  Those in nursing homes have a far less diverse microbiota 
and this has been attributed to a less varied diet35.  However, it is possible that 
pathological factors that lead to admission into nursing homes such as deteriorating 
cognitive function and less physical activity might play an important role in the decreased 
microbial richness and not the less diverse diet.  On-going studies should clarify this 
issue and there is a challenge for the food industry to produce diets for the elderly which 
will help to sustain microbial diversity. 
What is abundantly clear is that a dyregulated gut microbiota either in early childhood or 
in an aging population significantly increases the likelihood of brain dysfunction.  The 
precise relationship between these observations is far from understood.  Determining the 
mechanisms and pathways underlying microbiota-brain interactions may yield novel 
insights into individual variations and perhaps enable the development of new treatments 
for a range of neurodevelopmental and neurodegenerative disorders, ranging from autism 
to Parkinson’s disease.  
IBS as prototype 
IBS is the prototypic disorder of the brain-gut-microbiota axis, generally perceived as a 
having a biopsychosocial aetiology36 and frequently co-morbid with depression or 
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anxiety.. The most important single risk factors are female gender, younger age and 
preceding gastrointestinal infections.  Recent studies suggest that trauma in childhood 
especially sexual abuse may be an important risk factor37.  The aspect of dysbiosis in IBS 
is important and will be dealt with elsewhere, but aspects of gut to brain communication 
are clearly altered.  For example elevated levels of plasma pro-inflammatory cytokines 
are found and there is an exaggerated pituitary-adrenal response to corticotropin-releasing 
hormone, together with augmented visceral pain responses. A recent study found that 
fasting serum levels of SCFAs did not differ between patients with IBS and controls 38. 
However, the postprandial levels of total SCFAs, acetic acid, propionic acid, and butyric 
acid  were found to be significantly lower in patients with IBS compared with healthy 
controls. An epigenetic model of IBS has been proposed 36 which is consistent with the 
potential epigenetic modulating effects of butyrate, the levels of which are altered 
substantially in the post-prandial state.  
Treatments for IBS which do not take into account this complex pathophysiology are 
likely to be of very limited benefit. 
---Insert Fig 2 here-- 
Depression 
IBS and depression are frequently co-morbid and the latter is associated with the 
presence of biomarkers of inflammation such as elevated interleukin IL-6, tumor necrosis 
factor alpha (TNFα) and the acute phase protein, C reactive protein (CRP)(45). Similar 
elevated biomarkers of inflammation have been seen in anxiety states and are known to 
occur as a result of stress. The site at which these pro-inflammatory molecules is 
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produced in depression is not known and it has yet to be determined whether the 
elevation is core to the pathophysiology or merely epiphenomenal.  There is evidence 
from rodent studies to indicate that stress alters the gut barrier function allowing 
lipopolysaccharide (LPS) and other molecules to gain access to the bloodstream 
stimulating toll-like receptor 4 (TLR4)  and other TLRs resulting in the production of 
inflammatory cytokines (46). If this does occur in depression, which has yet to be 
definitively demonstrated, it would  explain the pro-inflammatory phenotype observed.   
The McMaster group using germ-free and specific pathogen-free mice, demonstrated that 
the early life stress of maternal separation alters the HPA and colonic cholinergic neural 
regulation in a microbiota-independent fashion 39. However, they showed that the 
microbiota is required for the induction of anxiety-like behaviour and behavioural 
despair. Colonization of adult germ-free maternally separated and control mice with the 
same microbiota produces distinct microbial profiles, which are associated with altered 
behaviour in maternally separated, but not in control mice. The results suggest that 
maternal separation-induced changes in host physiology lead to intestinal dysbiosis, 
which is a critical determinant of the abnormal behaviour that characterizes this model of 
early-life stress.  Prior studies in maternally separated rats demonstrated an altered 
behavioural phenotype when these animals reached maturity and also decreased diversity 
in the microbiota 20.   Does this decreased diversity translate to patients with major 
depression? 
 
In a recent study the faecal microbiota was sequenced40.    Forty-six patients with 
depression and 30 healthy controls were recruited. . High-throughput pyrosequencing 
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showed that, according to the Shannon index, increased fecal bacterial alpha-diversity 
was found in those currently depressed but not in a group who had responded to 
treatment . Bacteroidetes, Proteobacteria, and Actinobacteria were increased, whereas 
Firmicutes was significantly reduced.   Despite the profound inter-individual variability, 
levels of several predominant genera were significantly different between the depressives 
and controls. Most notably, the depressives had increased levels of Enterobacteriaceae 
and Alistipes but reduced levels of Faecalibacterium. The authors conclude that further 
studies are necessary to elucidate the temporal and causal relationships between gut 
microbiota and depression and to evaluate the suitability of the microbiome as a 
biomarker.   When rats are given a humanised microbiota from depressed patients as 
opposed to healthy controls they develop a depressive phenotype from a behavioural and 
immune perspective. 
 
Autism 
Autism is a neurodevelopmental disorder whose prevalence is apparently on the increase.  
It is characterised by a failure of language acquisition and a lack of sociability.  It is 
frequently associated with GI symptoms41 the relevance of which has been a longstanding 
source of controversy.   Up to 70% of patients with the syndrome report abdominal 
symptoms and hence the view that it is a disorder of the brain-gut axis.  Our group at the 
APC Microbiome Institute examined the behaviour of mice raised in a germ-free 
environment 42,43.  The mice were tested in a three chamber facility, where a germ-free 
mouse was placed in the middle chamber with a familiar mouse in one chamber and a 
novel mouse in the third. The germ-free mouse spent as much time with the familiar as 
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with the novel mouse; this is in contrast to the behaviour of conventionally colonised 
mice who spend more time with the novel than the familiar mouse. Germ-free mice are 
also more likely to spend time with an object than with another mouse, a decidedly 
abnormal behaviour for a sociable animal.  Colonisation of the germ free mice does 
partially normalise their behaviour patterns.  These behavioural changes are associated 
with significant alterations in underlying neurochemistry. 
Work from the late Paul Patterson & Sarkis Mazmanian’s group in an animal model 
demonstrated that the microbiota modulates behavioural and physiological abnormalities 
associated with neurodevelopmental disorders such as autism 44.  They used the maternal 
immune activation model induced by poly-IC injection during pregnancy and found 
altered gastrointestinal barrier defects and microbiota alterations.  Oral treatment with the 
human commensal Bacteroides fragilis was shown to correct gut permeability and most 
interestingly stereotyped and other abnormal behaviours.  Furthermore, a metabolite 
found in the abnormal animals was observed to transfer the phenotype to naïve animals 
and to be reduced by Bacteroides fragilis.  
Increasing attention is currently being paid to oxytocin the hypothalamic peptide which 
has been shown to increase sociability. The oxytocin receptor knockout mouse shows 
considerable deficits in social behaviour 45 and some small scale preliminary studies in 
humans indicate that intra-nasally administered oxytocin may positively alter social 
behaviour patterns.   A few large clinical trials are under way to test oxytocin and related 
therapies for autism spectrum disorder  46. There is still considerable debate as to whether 
or not the preclinical findings translate to the clinical setting and if they do which patients 
and which aspects of the syndrome are likely to benefit most.  Intriguingly, a recent study 
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indicates that a probiotic bacteria can influence hypothalamic posterior pituitary activity 
and increase oxytocin levels raising the possibility of influencing social behaviour by 
targeting the gut microbiota 47.  
The faecal microbiota in patients with autism spectrum disorder has been sequenced 48.  
In the most recently published study Tomova et al examined the microbiota in Slovakian 
children.  The faecal microbiota of autistic children showed a significant decrease of the 
Bacteroidetes/Firmicutes ratio and elevation of the amount of Lactobacillus spp.  There 
was a modest elevation in Desulfovibrio spp and a correlation with the severity of autism.  
A probiotic diet normalised the Bacteroidetes/Firmicutes ratio and Desulfovibrio spp 
levels.  As recently summarised by Mayer & colleagues there is a paucity of large 
comprehensive studies of the microbiome in autism 3. Again the issue of chicken or egg 
emerges; are these changes induced by stereotyped diets seen in many individuals as a 
product of obsessional behaviour patterns? Also the heterogeneous nature of the disease 
needs to be taken into account and  much more effort is needed to tease out the exact role 
of the microbiome in both the aetiology and treatment of the disorder. 
Parkinson’s disease 
In marked contrast to autism Parkinson’s disease tends to be diagnosed generally in old 
age; it is the second most common neurodegenerative disorder and affects 1-2% of the 
population over 65 years of age.  It is a movement disorder characterised by degeneration 
of the zona compacta neurons of the substantia nigra.  The most common GI symptoms 
are constipation, appetite loss, weight loss, dysphagia, sialorrhea and gastro-oesophageal 
reflux49.  Alpha-synuclein-aggregates, the major neuropathological marker in Parkinson’s 
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disease, are present in  the submucosal and myenteric plexuses of the enteric nervous 
system, prior to their detection in the brain, which may indicate a gut to brain "prion-like" 
spread 50.   
The gut microbiota has been sequenced in patients with Parkinson’s disease51. On 
average, the abundance of Prevotellaceae in the feces of Parkinson’s disease patients was 
reduced by almost 80% compared with controls. A logistic regression analysis based on 
the abundance of four bacterial families and the severity of constipation identified 
Parkinson’s disease  patients with 66.7% sensitivity and 90.3% specificity. The relative 
abundance of Enterobacteriaceae was highly correlated with the severity of postural 
instability and gait difficulty. The findings suggest that the intestinal microbiome is 
altered in Parkinson’s disease and is related to motor phenotype. Large prospective 
studies beginning in the early stages of the disorder are required. 
It has been suggested  that microbiota transplantation might benefit patients with 
Parkinson’s disease but there is as yet no conclusive evidence52.  Neither are there any 
reports of controlled trials of probiotics/psychotiotics. 
Psychobiotics 
Psychobiotics were first defined as the family of probiotics that, ingested in appropriate 
quantities, had a positive mental health benefit53.   Recently, the definition has been 
expanded to include prebiotics, which are dietary, soluble fibres for example 
galactooligosaccharides (GOS) or fructooligosaccharides (FOS) that stimulate the growth 
of intrinsic commensal microbiota.  There is now an enormous volume of preclinical data 
to support the concept of psychobiotics.  Understandably, clinical data is less abundant 
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but nonetheless is emerging.  Given the demonstrated efficacy of probiotics in IBS54 and 
the high co-morbidity between IBS and stress related mental health issues such as anxiety 
and depression it is not surprising that certain probiotics might positively impact on 
mental health. 
Tillisch et al 55 administered  healthy female participants either a placebo or a mixture of 
probiotics (Bifidobacterium animalis Lactis, Streptococcus thermophiles, Lactobacillus 
bulgaricus, and Lactococcus lactis Lactis), which were consumed over four weeks. 
Participants underwent functional magnetic resonance imaging (fMRI) to determine how 
probiotic ingestion affected neuropsychological activity. During image acquisition, 
participants were shown emotional faces that are known to capture attention and cause 
brain activation.  Relative to placebo, probiotic-treated participants showed decreased 
activity in a functional network associated with emotional, somatosensory, and 
interceptive processing, including the somatosensory cortex, the insula, and the 
periaqueductal gray. In marked contrast, placebo participants showed increased activity 
in these regions in response to emotional faces. This is interpreted as evidence of a 
probiotic-induced reduction in network-level neural reactivity to negative emotional 
information. 
A recent prebiotic study carried out in Oxford found a significant impact on stress 
responses 56. Healthy male and female participates consumed either BGOS, FOS, or a 
placebo. In comparison to the other two groups, participants who consumed BGOS 
showed significantly reduced waking-cortisol responses, which are a robust marker  of 
anxiety, stress, and depression risk 57. Furthermore, participants completed an emotional 
dot-probe task measuring vigilance, or attention to negative stimuli, which is also a 
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marker of anxiety and depression. Participants taking BGOS showed substantially 
attenuated vigilance on this task, suggesting reduced attention and reactivity to negative 
emotions. Overall, the data support the view that the specific prebiotic has anxiolytic 
activity. 
Takada et al 58 examined the effects of Lactobacillus casei strain Shirota (LcS) on gut-
brain interactions under stressful conditions. A double-blind, placebo-controlled trials 
were conducted to examine the effects of LcS on psychological and physiological stress 
responses in healthy medical students whilst undergoing examination stress. Subjects 
received LcS-fermented milk or placebo daily for 8 weeks prior to taking an examination. 
Subjective anxiety scores, salivary cortisol, and the presence of physical symptoms were 
analysed.  In a parallel animal study, rats were fed a diet wither with or without LcS for 2 
weeks, then submitted to water avoidance stress (WAS). Plasma corticosterone 
concentration and the expression of cFos and corticotropin releasing factor (CRF) in the 
paraventricular nucleus (PVN) were measured immediately after WAS. Academic stress 
resulted in increases in salivary cortisol and an increase in physical symptoms, both of 
which were significantly suppressed in the LcS group. In rats pretreated with LcS, WAS-
induced increases in plasma corticosterone were significantly suppressed, and the number 
of CRF-expressing cells in the PVN was reduced. Intriguingly, intragastric administration 
of LcS was found to stimulate gastric vagal afferent activity in a dose-dependent manner. 
The results suggest that LcS may positively impact stress responses by acting through the 
vagus nerve. In a study of university students we have found that a Bifidobacterium 
longum decreased morning waking cortisol levels, reduced subjective levels of anxiety 
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and modestly improved aspects of cognitive functioning, an effect that was associated 
with altered EEG activity. 
A large scale cross-sectional study has examined the impact of probiotics on measures of 
social anxiety59.  Seven hundred and ten young adults completed self-report measures of 
fermented food consumption, neuroticism, and social anxiety. An interaction model, 
controlling for demographics, general consumption of healthful foods, and exercise 
frequency, showed that exercise, neuroticism, and fermented food consumption 
significantly and independently predicted social anxiety. Furthermore, fermented food 
consumption also interacted with neuroticism in predicting social anxiety. For those with  
high neuroticism scores, a high frequency of fermented food consumption resulted in 
fewer symptoms of social anxiety.  The data suggest that fermented foods containing 
probiotics may have a protective effect against social anxiety symptoms for those at 
higher genetic risk, as assayed by trait neuroticism.  
Sternbergen et al 60 tested  a multispecies probiotic containing Bifidobacterium bifidum, 
Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus 
casei, Lactobacillus salivarius, and Lactococcus lactis  in non-depressed individuals 
using a triple-blind, placebo-controlled, randomized, design, Twenty healthy participants 
received a 4-week probiotic food-supplement intervention with the multispecies 
probiotics, while 20 control participants received an inert placebo for the same period.  
Subjects who received the 4-week multispecies probiotics intervention showed a 
significantly reduced overall cognitive reactivity to sad mood. The results provide 
evidence that probiotics may help reduce negative thoughts associated with sad mood.  
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Romijn and Rucklidge in their systematic review 61 add a  note of caution to the above 
optimistic findings concluding that more trials are necessary before any definitive 
inferences can be made about the efficacy of probiotics in mental health applications.  
Further studies of a translational nature are certainly required. 
Summary/Discussion 
The role of the microbiota-gut-brain access in the genesis of IBS symptoms is now 
largely accepted, though several questions remain unanswered.  How does stress, 
especially early life stress dysregulate the axis?  Can IBS subtypes be delineated on the 
basis of the microbiota?  If patients with IBS have co-morbid psychiatric illness does the 
latter resolve if the former is treated with probiotics?  
We have an enormous number of pre-clinical studies implicating the gut microbiota in 
other stress-related conditions and in disorders at the extremes of life.  Far more 
translational studies are required.  The human studies to date support the view that the gut 
microbiota is altered in major depression and that psychobiotics, either in the form of 
prebiotics or probiotics van impact anxiety and depressive symptoms in healthy subjects.  
We have no clear indication of efficacy in diseased populations.  In the 
neurodevelopmental disorder autism, which is usually diagnosed in early childhood, GI 
symptoms are common and an altered microbiota has been reported, while at the other 
end of the developmental spectrum old age related frailty correlates with decreased gut 
microbial diversity.   Whether fecal microbiota transplantation is an appropriate 
therapeutic option in at least some brain-gut axis disorders remains to be determined. 
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Fig 1 Routes of communication between gut microbes and brain.  These include the 
vagus nerve, short chain fatty acids (butyrate, propionate, acetate), cytokines and 
tryptophan 
 
Fig 2  Model of irritable bowel syndrome.  Psychological stress or infection leads to 
activation of the hypothalamic-pituitary-adrenal-axis (HPA) with elevation in 
cortisol and also changes in gut permeability. Lipopolysaccharide (LPS) enters the 
bloodstream increasing pro-inflammatory cytokines and in turn altering tryptophan 
metabolism.  In turn this leads to alterations in 5HT and glutamate 
neurotransmission.  Psychobiotics may impact by decreasing gut permeability and 
signaling the brain via the vagus nerve and other routes. 
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